がん免疫療法の世界市場：2025年～2033年

世界のがん免疫療法の市場規模は、2024年に1,377億米ドルに達し、2033年には2,617億4,000万米ドルに達すると予測され、2025年から2033年の予測期間中のCAGRは 7.9％と見込まれています。

免疫腫瘍学とも呼ばれるがん免疫療法は、がんを予防、管理、除去するために身体の免疫システムを活用するがん治療アプローチです。免疫系ががん細胞を識別し、より効果的に標的化する能力を強化します。この方法は、腫瘍細胞に存在するユニークな抗原を利用するもので、抗原が適切に同定されれば、免疫系がそれを認識して攻撃できるようになります。この市場には、免疫チェックポイント阻害剤、モノクローナル抗体、がんワクチン、CAR-T細胞療法、サイトカインなど、いくつかの主要な治療アプローチが含まれます。

がん罹患率の上昇は、がん免疫療法市場の成長促進要因です。肺がん、乳がん、大腸がんなどの有病率は上昇を続けており、特に国際がん研究機関が2022年に世界で新たに報告した症例数は1,998万例であることから、より効果的で的を絞った治療オプションに対するニーズが高まっています。

また、米国国立衛生研究所によれば、2025年までに米国だけで204万人の新規がん患者が発生するとされています。特に肺がんは、依然として世界で最も多く診断され、がんに関連した死亡の主な原因となっており、その数は250万人近くにのぼります。これらすべての要因が世界のがん免疫療法市場を牽引しています。

このようながん患者の憂慮すべき増加は、免疫療法の需要を促進しています。免疫療法は、標的を絞る性質と低毒性により、化学療法のような従来の治療に代わる効果的な治療法としてますます注目されています。がんの負担が増大するにつれて、革新的な治療法に対するニーズは加速し、研究への投資増加や新たな免疫療法の開発に拍車をかけています。このように、上記の要因は今後もがん免疫療法市場の拡大に拍車をかけると予想されます。

免疫療法の治療費が高額であることが、がん免疫療法市場の成長を阻害すると予想されます。実験的ながん免疫療法のフルコースは平均3万米ドルから4万米ドルであるため、多くの患者はこれらの治療法を利用する上で経済的な障壁に直面する可能性があります。この高額な費用は患者に大きな負担を強いるだけでなく、ヘルスケアシステムや保険プロバイダーにも負担を強います。

免疫療法の治療レジメンの中には、治療期間の延長や長期にわたる複数回の投与が必要なものもあり、患者の総費用はさらに増加します。継続的な費用負担は、個人にとってもヘルスケアプロバイダーにとっても管理が難しいです。その結果、これらの治療が手ごろな価格で受けられるかどうかにより、治療の普及が制限され、市場への浸透が遅れ、これらの先進治療の恩恵を受けられる患者へのアクセスが低下する可能性があります。このように、上記の要因が世界のがん免疫療法市場の潜在的な成長を制限している可能性があります。

当レポートでは、世界のがん免疫療法市場について調査し、市場の概要とともに、製品タイプ別、適応症別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界見通し

• 市場のリーダーとパイオニア
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 がん免疫療法市場（製品タイプ別）

• 免疫チェックポイント阻害剤
• モノクローナル抗体
• サイトカイン
• がんワクチン
• 養子細胞療法
• 腫瘍溶解性ウイルス
• その他

第6章 がん免疫療法市場（適応症別）

• 非小細胞肺がん（NSCLC）
• 黒色腫
• 大腸がん
• 腎細胞がん
• 乳がん
• 膀胱がん
• その他

第7章 がん免疫療法市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第8章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第9章 企業プロファイル

• Amgen Inc.
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Merck &Co., Inc.
• AstraZeneca
• Pfizer Inc.
• Johnson &Johnson Services, Inc.
• Incyte
• Dendreon Pharmaceuticals LLC.
• Kite Pharma, Inc.

第10章 仮定と調査手法

第11章 付録

The global cancer immunotherapy market reached US$ 137.70 billion in 2024 and is expected to reach US$ 261.74 billion by 2033, growing at a CAGR of 7.9% during the forecast period of 2025-2033.

Cancer immunotherapy, also called immuno-oncology, is a cancer treatment approach that leverages the body's immune system to prevent, manage, and eliminate cancer. It enhances the immune system's ability to identify and target cancer cells more effectively. This method takes advantage of the unique antigens present in tumor cells, allowing the immune system to recognize and attack them once these antigens are properly identified. This market includes several key treatment approaches, such as immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, CAR-T cell therapies, and cytokines.

Market Dynamics: Drivers & Restraints

Increasing Incidence of Cancer Cases

The increasing incidence of cancer is a key driver for the growth of the cancer immunotherapy market. As the prevalence of cancers such as lung, breast, and colorectal continues to rise, particularly with 19.98 million new cases reported globally in 2022 by the International Agency for Research on Cancer, there is a growing need for more effective and targeted treatment options.

Additionally, according to the National Institutes of Health, there will be 2.04 million new cancer cases in the U.S. alone by 2025. Lung cancer, in particular, remains the most commonly diagnosed and the leading cause of cancer-related deaths worldwide, with nearly 2.5 million cases. All these factors drive the global cancer immunotherapy market.

This alarming rise in cancer cases is driving demand for immunotherapies, which are increasingly seen as an effective alternative to traditional treatments like chemotherapy due to their targeted nature and lower toxicity. As the burden of cancer grows, the need for innovative therapies accelerates, spurring increased investment in research and the development of new immunotherapy options. Thus, the above factor is expected to continue fueling the expansion of the cancer immunotherapy market.

High Cost of Treatment

The high cost of immunotherapy treatments is expected to hinder the growth of the cancer immunotherapy market. With a full course of experimental cancer immunotherapy averaging between $30,000 and $40,000, many patients may face financial barriers to accessing these therapies. This high cost not only places a significant burden on patients but also strains healthcare systems and insurance providers.

Some immunotherapy treatment regimens require extended treatment periods or multiple doses over time, further increasing overall costs for patients. The ongoing cost burden can be difficult to manage for both individuals and healthcare providers. As a result, the affordability of these treatments may limit their widespread adoption, slow market penetration, and reduce access for patients who could benefit from these advanced therapies. Thus, the above factors could be limiting the global cancer immunotherapy market's potential growth.

Segment Analysis

The global cancer immunotherapy market is segmented based on product type, indication, and region.

Product Type:

The monoclonal antibodies segment in product type is expected to dominate the global cancer immunotherapy market with the highest market share

Monoclonal antibodies (mAbs) are laboratory-made proteins that mimic the immune system's ability to fight harmful pathogens. In cancer immunotherapy, these antibodies specifically target cancer cells by recognizing unique antigens on their surface.

The monoclonal antibodies (mAbs) segment is primarily driven by extensive research and development investments, technological advancements, and their effectiveness in treating various types of cancer. Monoclonal antibodies are widely used in targeting specific cancer cells while minimizing damage to healthy tissues, making them a preferred choice in immunotherapy. The market is also expanding due to increasing cancer prevalence, rising awareness of immunotherapy treatments, and regulatory approvals that accelerate the availability of new drugs.

Furthermore, key players' strategies, such as partnerships and collaborations, would propel this segment's growth in the market. For instance, in March 2023, BioNTech SE and OncoC4, Inc. entered into a global licensing and collaboration agreement to develop and commercialize ONC-392, a next-generation anti-CTLA-4 monoclonal antibody.

This agreement gives BioNTech exclusive worldwide rights to further advance this experimental cancer treatment, either as a standalone therapy (monotherapy) or in combination with other treatments. These factors have solidified the segment's position in the global cancer immunotherapy market.

Geographical Analysis

North America is expected to hold a significant position in the global cancer immunotherapy market, with the highest market share

North America is expected to maintain its dominance in the cancer immunotherapy market throughout the forecast period, driven by the region's high cancer incidence and growing demand for innovative treatments. The American Cancer Society projects 226,650 new lung cancer cases in 2025 alone, contributing to an increased need for cancer immunotherapies. With this, the number of individuals who approach cancer immunotherapy is also expected to rise.

In addition to the increasing number of cancer cases, North America benefits from strong governmental support and significant funding directed at cancer research. This funding fosters the development of new therapies and accelerates their introduction to the market. Moreover, the region is a global leader in research and development, with major pharmaceutical companies and renowned research institutions driving continuous progress in oncology treatments.

North America's regulatory environment also plays a key role in this dominance. For instance, in May 2024, Amgen received accelerated approval of IMDELLTRA (tarlatamab-dlle), a breakthrough immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after platinum-based chemotherapy. This approval highlights the region's capability to fast-track innovative cancer treatments. With these factors, North America is expected to remain a dominant force in the global cancer immunotherapy market, driving both demand and development for new cancer therapies.

Competitive Landscape

The major global players in the cancer immunotherapy market include Amgen Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca, Pfizer Inc., Johnson & Johnson Services, Inc., Incyte, Dendreon Pharmaceuticals LLC., and Kite Pharma, Inc., among others.

Key Developments

• In September 2024, Roche received the U.S. Food and Drug Administration (FDA) approval for Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy.
• In January 2024, Boehringer Ingelheim and 3T Biosciences entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer immunotherapy market report delivers a detailed analysis with 54 key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Indication
• 2.5. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Incidence of Cancer Cases
    • 3.1.1.2. Rising Investment and Funding
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of Treatment
    • 3.1.2.2. Side Effects Associated with Treatment
  • 3.1.3. Opportunity
    • 3.1.3.1. Rising Number of Clinical Trials
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Cancer Immunotherapy Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Immune Checkpoint Inhibitors*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Atezolizumab
  • 5.2.4. Avelumab
  • 5.2.5. Nivolumab
  • 5.2.6. Pembrolizumab
  • 5.2.7. Durvalumab
  • 5.2.8. Ipilimumab
  • 5.2.9. Others
• 5.3. Monoclonal Antibodies
• 5.4. Cytokines
• 5.5. Cancer Vaccines
  • 5.5.1. Preventive Vaccines
  • 5.5.2. Therapeutic Vaccines
• 5.6. Adoptive Cell Therapy
  • 5.6.1. Tumor Infiltrating Lymphocyte (TIL) Therapy
  • 5.6.2. Engineered T-Cell Receptor (TCR) Therapy
  • 5.6.3. Chimeric Antigen Receptor (CAR) T Cell Therapy
  • 5.6.4. Natural Killer (NK) Cell Therapy
• 5.7. Oncolytic Virus
• 5.8. Other Immunotherapies

6. Cancer Immunotherapy Market, By Indication

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 6.1.2. Market Attractiveness Index, By Indication
• 6.2. Non-Small Cell Lung Cancer (NSCLC)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Melanoma
• 6.4. Colorectal Cancer
• 6.5. Renal Cell Carcinoma
• 6.6. Breast Cancer
• 6.7. Bladder Cancer
• 6.8. Others

7. Cancer Immunotherapy Market, By Regional Market Analysis and Growth Opportunities

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 7.1.2. Market Attractiveness Index, By Region
• 7.2. North America
  • 7.2.1. Introduction
  • 7.2.2. Key Region-Specific Dynamics
  • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.2.5.1. U.S.
    • 7.2.5.2. Canada
    • 7.2.5.3. Mexico
• 7.3. Europe
  • 7.3.1. Introduction
  • 7.3.2. Key Region-Specific Dynamics
  • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.3.5.1. Germany
    • 7.3.5.2. U.K.
    • 7.3.5.3. France
    • 7.3.5.4. Spain
    • 7.3.5.5. Italy
    • 7.3.5.6. Rest of Europe
• 7.4. Latin America
  • 7.4.1. Introduction
  • 7.4.2. Key Region-Specific Dynamics
  • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.4.5.1. Brazil
    • 7.4.5.2. Argentina
    • 7.4.5.3. Rest of Latin America
• 7.5. Asia-Pacific
  • 7.5.1. Introduction
  • 7.5.2. Key Region-Specific Dynamics
  • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.5.5.1. China
    • 7.5.5.2. India
    • 7.5.5.3. Japan
    • 7.5.5.4. South Korea
    • 7.5.5.5. Rest of Asia-Pacific
• 7.6. Middle East and Africa
  • 7.6.1. Introduction
  • 7.6.2. Key Region-Specific Dynamics
  • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8. Competitive Landscape and Market Positioning

• 8.1. Competitive Overview and Key Market Players
• 8.2. Market Share Analysis and Positioning Matrix
• 8.3. Strategic Partnerships, Mergers & Acquisitions
• 8.4. Key Developments in Product Portfolios and Innovations
• 8.5. Company Benchmarking

9. Company Profiles

• 9.1. Amgen Inc.*
  • 9.1.1. Company Overview
  • 9.1.2. Product Portfolio
    • 9.1.2.1. Product Description
    • 9.1.2.2. Product Key Performance Indicators (KPIs)
    • 9.1.2.3. Historic and Forecasted Product Sales
    • 9.1.2.4. Product Sales Volume
  • 9.1.3. Financial Overview
    • 9.1.3.1. Company Revenue
    • 9.1.3.2. Geographical Revenue Shares
    • 9.1.3.3. Revenue Forecasts
  • 9.1.4. Key Developments
    • 9.1.4.1. Mergers & Acquisitions
    • 9.1.4.2. Key Product Development Activities
    • 9.1.4.3. Regulatory Approvals, etc.
  • 9.1.5. SWOT Analysis
• 9.2. F. Hoffmann-La Roche Ltd
• 9.3. Bristol-Myers Squibb Company
• 9.4. Merck & Co., Inc.
• 9.5. AstraZeneca
• 9.6. Pfizer Inc.
• 9.7. Johnson & Johnson Services, Inc.
• 9.8. Incyte
• 9.9. Dendreon Pharmaceuticals LLC.
• 9.10. Kite Pharma, Inc.

LIST NOT EXHAUSTIVE

10. Assumptions and Research Methodology

• 10.1. Data Collection Methods
• 10.2. Data Triangulation
• 10.3. Forecasting Techniques
• 10.4. Data Verification and Validation

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us